Development and validation of sensitive and selective LC-MS/MS methods for the determination of BMS-708163, a γ-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions
スポンサーリンク
概要
- 論文の詳細を見る
- 2010-09-01
著者
-
Aubry Anne-francoise
Bioanalytical Sciences Research & Development Bristol-myers Squibb Company
-
GU Huidong
Bioanalytical Sciences, Research & Development, Bristol-Myers Squibb Company
-
DENG Yuzhong
Bioanalytical Sciences, Research & Development, Bristol-Myers Squibb Company
-
WANG Jian
Bioanalytical Sciences, Research & Development, Bristol-Myers Squibb Company
-
ARNOLD Mark
Bioanalytical Sciences, Research & Development, Bristol-Myers Squibb Company
-
Deng Yuzhong
Bioanalytical Sciences Research & Development Bristol-myers Squibb Company
-
Gu Huidong
Bioanalytical Sciences Research & Development Bristol-myers Squibb Company
-
Arnold Mark
Bioanalytical Sciences Research & Development Bristol-myers Squibb Company
-
Arnold Mark
Bioanalytical Sciences Department Pharmaceutical Research Institute
-
Wang Jian
Bioanalytical Sciences Research & Development Bristol-myers Squibb Company
関連論文
- Development and validation of sensitive and selective LC-MS/MS methods for the determination of BMS-708163, a γ-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions
- Simultaneous determination of a selective adenosine 2A agonist, BMS-068645, and its acid metabolite in human plasma by liquid chromatography-tandem mass spectrometry-Evaluation of the esterase inhibitor, diisopropyl fluorophosphate, in the stabilization o
- Liquid chromatography and tandem mass spectrometry for the quantitative determination of ixabepilone (BMS-247550, Ixempra^) in human plasma : Method validation, overcoming curve splitting issues and eliminating chromatographic interferences from degra